Follow us on Twitter
twitter icon@FreshPatents


Immune Diseases patents

      

This page is updated frequently with new Immune Diseases-related patent applications.




 Fluorometric immunoassay for detection of anti-dsdna antibodies patent thumbnailnew patent Fluorometric immunoassay for detection of anti-dsdna antibodies
The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded dna (dsdna) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (sle). The fluorometric immunoassay method for detection of anti-dsdna solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard farr-ria method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%).
Univerzitetni Klinicni Center Ljubljana


 Tlr3 binding agents patent thumbnailnew patent Tlr3 binding agents
The present invention relates to antibodies (e.g. Monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind tlr3, and that optionally further modulate, e.g.
Innate Pharma


 Compositions and methods of use for therapeutic antibodies patent thumbnailnew patent Compositions and methods of use for therapeutic antibodies
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag


 Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein patent thumbnailnew patent Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein
A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital


 Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same patent thumbnailnew patent Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.

 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor patent thumbnailBenzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


 S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7 patent thumbnailS-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7
The present invention relates to a family of s-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (pde7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.. .
Consejo Superior De Lnvestigaciones Cientificas (csic)


 Antigen-specific immunotherapy using tolerizing liposomes patent thumbnailAntigen-specific immunotherapy using tolerizing liposomes
The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh


 Liposome-based immunotherapy patent thumbnailLiposome-based immunotherapy
The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats


 Nucleic acid capable of inhibiting expression of beta-2gpi patent thumbnailNucleic acid capable of inhibiting expression of beta-2gpi
The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.


Baff selective binding compounds and related methods

The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.

Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and related therapies

Improved anti-cd154 antibodies are provided herein which have ablated fcr binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein..
The Trustees Of Dartmouth College

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Tnfa-il-17 bispecific antibodies

Bispecific tetravalent antibodies against il-17 and tnfa, useful in therapy, e.g. The treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions..
Hoffmann-la Roche Inc.

Derivatives of tartaric acid

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Use of cd83 in combination therapies

The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.

Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier

A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (a) comprising at least one of a probiotic that is any one of lactic acid bacteria, lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of lactobacillus bifidus, and others or a mixture thereof and an ingredient (b) comprising at least one of l-glutamine, zinc, vitamin a and vitamin d.. .

Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.

Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

And pharmaceutically acceptable derivatives thereof. Methods of treatment of neoplastic and autoimmune diseases with these compounds are also disclosed..

Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.

Particles containing phospholipids or bioactive fatty acids and uses thereof

The subject matter disclosed herein is directed to particles containing phospholipids and/or fatty acids and the uses thereof for treating autoimmune diseases, inflammatory diseases and for modulating immune and inflammatory responses. Methods of preparing the particles are also described..
The University Of North Carolina At Chapel Hill

Substituted anilines as ccr(4) antagonists

Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Halofuginone analogs for inhibition of trna synthetases and uses thereof

The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications..
Children's Medical Center Corporation

Pyridinyl and fused pyridinyl triazolone derivatives

Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk..

Pharmaceutical compositions comprising dimethyl fumarate

Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch, and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders..
Almirall, S.a.

Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

The present application discloses a novel fusion peptide of il-2 and il-33 and its use. It comprises a biologically active domain of interleukin-2 (il-2) or a biologically active fragment or homolog thereof, and a biologically active domain of interleukin-33 (il-33) or a biologically active fragment or homolog thereof.
University Of Virginia Patent Foundation

Furo[3,4-b]pyran compounds and pharmaceutical uses

Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited

Novel compounds

The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.



Immune Diseases topics:
  • Immune Diseases
  • Autoimmune
  • Immune Disease
  • Autoimmune Disease
  • Autoimmune Diseases
  • Immune Disorder
  • Rheumatoid Arthritis
  • Antibodies
  • Antagonist
  • Nucleotide
  • Proliferative
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Type 1 Diabetes


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.5893

    file did exist - 2961

    2 - 1 - 56